Plant Phenolic Compounds Show Promise Against Disease, but Human Evidence Lags

Plant phenolic compounds have become one of the most intensively studied groups of dietary molecules in biomedical research, and a new open-access review published in the journal Discover Molecules on 16 July 2026 brings together what is known about their chemistry, their journey through the human body, and their potential role in preventing diseases linked to oxidative stress. The review, written by an international team of researchers led by Abraham De La Cruz and Cristian Torres-León, examines everything from the molecular mechanisms by which phenolics neutralize reactive oxygen species to the barriers that limit how much of these compounds actually reaches human tissues, including the brain.

The starting point for the review is oxidative stress, defined as a disruption in the balance between the generation of reactive oxygen species, or free radicals, and the body’s inherent antioxidant defenses. Normal biological processes such as respiration, digestion, alcohol metabolism, and fat metabolism continuously generate free radicals, and the body’s antioxidant system normally eliminates them. When that system malfunctions, a chain reaction can damage cell membranes, hinder crucial enzymes, disrupt cellular processes, inhibit normal cell division, damage DNA, and impede energy production. Oxidative stress has been implicated as a key factor in the progression of illnesses ranging from cancer to neurodegenerative diseases, which is why strategies to counter it attract so much research attention.

Phenolic compounds are secondary plant metabolites found in fruits, vegetables, legumes, tea, wine, and coffee, and roughly 8,000 of them have been identified in scientific studies. The review classifies them into two main groups: flavonoids, whose structure features a heterocyclic ring with an oxygen atom attached to two aromatic rings, and non-flavonoids, which include phenolic acids derived from benzoic and cinnamic acid as well as lignans, tannins, stilbenes, and coumarins. Their biological activity depends heavily on structural features such as the number and position of hydroxyl groups, glycosylation, molecular size, and degree of polymerization. Waste and byproducts from fruit and vegetable processing have also gained value as sources of these compounds, although complex molecules such as condensed tannins can present antinutritional challenges that bioprocesses like hydrolysis are used to resolve.

A substantial portion of the review is devoted to the chemistry of how phenolics act as antioxidants. They are classified as primary antioxidants because they directly neutralize free radicals through hydrogen atom transfer and single-electron transfer processes. The authors describe three principal pathways: proton-coupled electron transfer, in which the antioxidant donates a hydrogen atom to a radical and leaves behind a resonance-stabilized phenoxyl radical; electron transfer followed by proton transfer, governed by the molecule’s ionization potential; and sequential proton loss electron transfer, which is generally favored in polar, aqueous environments and is often considered the dominant pathway in biological systems. The thermodynamic feasibility of each route depends on parameters such as bond dissociation enthalpy, ionization potential, proton dissociation enthalpy, proton affinity, and electron transfer enthalpy, meaning antioxidant performance is a dynamic balance shaped by molecular structure, solvent polarity, pH, temperature, and the nature of the radical involved.

The review also situates phenolics within the body’s broader antioxidant defense system, which includes enzymatic components such as superoxide dismutase, catalase, glutathione peroxidase, peroxiredoxin, and glutathione S-transferase, alongside non-enzymatic antioxidants like glutathione, melatonin, vitamins C and E, carotenoids, and flavonoids. Phenolic compounds are reported to act as antioxidant agents by modulating cellular processes including apoptosis, redox balance signaling, differentiation, and proliferation. The authors note that small quantities of reactive oxygen species can even serve as molecular signal transducers, but excess production leads to protein and lipid oxidation and DNA damage, and that reducing ROS generated by unhealthy lifestyle choices may require external antioxidants.

Perhaps the most sobering section of the review concerns bioavailability. Phenolic compounds are treated by the body as xenobiotic substances with limited absorbability. Absorption begins in the mouth during chewing, where salivary enzymes and bacterial beta-glucosidase start breaking glycosidic residues, and the acidic gastric environment promotes hydrolysis. In the small intestine, enzymes such as cytosolic beta-glucosidase and lactase-phloridzin hydrolase liberate free flavonoid aglycones and phenolic acids, which are absorbed via sodium-dependent glucose transporters, monocarboxylic acid transporters, and simple diffusion. Yet only approximately 5 to 10 percent of ingested phenolic compounds are absorbed in the small intestine; the majority reach the colon, where gut microbiota degrade residual bound phenolics into simpler compounds available for absorption. Overall, only a small fraction, typically 1 to 10 percent, of the phenolic compounds consumed can be found in plasma and urine samples, with native compounds typically present at nanomolar to micromolar concentrations. Consuming 10 to 100 milligrams of a single phenolic compound has been observed to yield plasma concentrations of around 1 micromolar.

These pharmacokinetic realities carry a critical caveat that the authors emphasize repeatedly: many in vitro experiments reporting potent antioxidant, anti-inflammatory, and cytoprotective effects use concentrations that exceed those achievable in human plasma after dietary intake, leaving the physiological relevance of many experimental observations uncertain. Bioavailability also varies substantially between individuals due to differences in gut microbiota composition and host factors including age, sex, genetic background, dietary habits, and health status, which contributes to the heterogeneous responses and inconsistent efficacy seen in human studies. The health effects of phenolic intake remain a subject of investigation, and it is still unclear whether they stem from the compounds themselves, their bioavailable metabolites and catabolites, or alterations in intestinal microbial ecology.

Against that backdrop, the review surveys disease-specific evidence, most of which comes from preclinical work. In animal models of neurodegeneration, ellagic acid reduced mutant huntingtin levels, alleviated neuroinflammation, prevented synapse loss, and mitigated oxidative stress in R6/2 mice; 7-O-esters of taxifolin enhanced short-term memory in amyloid-beta-induced mice; the coffee-derived compound 5-caffeoylquinic acid showed potential to prevent cognitive dysfunction and inhibit amyloid-beta plaque formation in an APP/PS2 mouse model of Alzheimer’s disease; curcumin reduced oxidative stress in male Swiss mice with amyloid-beta-induced disease; and gallic acid prevented LPS-induced programmed cell death of nigrostriatal dopaminergic neurons in rats. Epigallocatechin-3-gallate, the green tea polyphenol, reduced rotenone-induced neurotoxicity in rats by decreasing nitric oxide levels and lipid peroxidation while increasing succinate dehydrogenase activity, ATPase levels, and striatal catecholamines. In metabolic disease research, phenolic acids were reported to enhance expression of the glucose transporter GLUT2 in pancreatic beta cells and to inhibit the carbohydrate-digesting enzymes alpha-glucosidase and alpha-amylase, while buckwheat husk flavonoids improved glucose tolerance and insulin sensitivity in diabetic mice. In cancer models, Jaboticaba peel extracts reduced malignant prostatic lesions in mice, EGCG attenuated immunosuppressive effects in a murine breast cancer model, and luteolin reduced tumor volumes in a bladder cancer xenograft model. In cardiovascular work, phenolic compounds decreased carbonylation of human plasma proteins and inhibited superoxide generation and thrombin-induced platelet activation in an in vitro model using human blood platelets.

The gut-brain connection receives particular attention. Phenolic metabolites produced by gut microbiota can act as neuromodulators, either by directly crossing the blood-brain barrier or by indirectly influencing the cerebrovascular system, and the gut-microbiota-brain axis is described as a bidirectional neuroendocrine system with significant impact on stress responses. A cited study of blood-brain barrier permeability found that epigallocatechin, daidzein, genistein, equol, and nobiletin showed high permeability, while apigenin, luteolin, quercetin, and kaempferol showed medium permeability. Anthocyanins were observed in various brain regions of rats given blueberry or blackberry extracts, and in a human study measuring 12 compounds in cerebrospinal fluid from 28 patients undergoing diagnostic lumbar puncture, homovanillic acid, 3-hydroxyphenylacetic acid, and caffeic acid were detected and correlated with plasma concentrations. Nevertheless, the authors stress that reliable data on the absorption and distribution of phenolic compounds in animal brains remain scarce, that most mechanisms have been characterized only in cell cultures and animal models, and that direct evidence in humans is limited.

The review’s conclusion is measured rather than triumphant. Although substantial evidence from preclinical and clinical studies suggests an association between polyphenol-rich diets and potentially reduced risk of certain chronic diseases, most findings derive from preclinical studies, and the magnitude of effects varies with phenolic composition, experimental models, dosage, treatment duration, and study design. The authors call for well-designed human intervention studies and randomized controlled trials to evaluate efficacy, safety, pharmacokinetics, and optimal dosage, along with standardized phenolic preparations, quantitative assessments of blood-brain barrier transport, and strategies such as nanoencapsulation to improve bioavailability. They also flag the dose-response relationship and the interaction between phenolic compounds and gut microbiota as fields whose exploration could reshape understanding of the physiological benefits of these ubiquitous plant molecules.

Subject of Research: The chemistry, bioavailability, and disease-prevention potential of plant phenolic compounds

Article Title: Phenolic compounds in human health from biofunctionality and bioavailability to gut brain interactions and disease prevention

Article References: De La Cruz, A., Silva, T. G., Verma, D. K., López-Yerena, A., Wong-Paz, J., Aguilar, C. N., Ramírez-Guzmán, N., & Torres-León, C. (2026). Phenolic compounds in human health from biofunctionality and bioavailability to gut brain interactions and disease prevention. Discover Molecules, 3(1), Article 23. https://doi.org/10.1007/s44345-026-00067-7

Image Credits: AI Generated

DOI: 10.1007/s44345-026-00067-7

Keywords: phenolic compounds, polyphenols, oxidative stress, antioxidants, bioavailability, gut microbiota, blood-brain barrier, neurodegenerative diseases, type 2 diabetes, cancer, cardiovascular disease, flavonoids